TrialClinical trialPHN-02592026-04-29 19:00 CT
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Source · ClinicalTrials.gov: survodutide
TLDR
ClinicalTrials.gov lists SYNCHRONIZE-MASLD as completed, a study testing survodutide against placebo for reducing liver fat and body weight in adults with overweight or obesity and presumed or confirmed NASH. Participants were assigned randomly to two groups; the provided excerpt contains no results.
01—Key points
- 01Participants and doctors did not know which treatment group participants were assigned to.
- 02The study planned to compare body weight and liver imaging findings between groups and monitor unwanted effects.
- 03Participation lasted about 1 year and 3 months, with diet and exercise counselling included for all participants.
Why it matters Editorial
The completed study addresses whether survodutide reduces liver fat and weight in this population, but the excerpt does not establish efficacy or safety outcomes.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.